Last reviewed · How we verify
NCT03461588
Prospective Assessment of Radiation-induced Heart Injury in Left-sided Breast Cancer
NA trial testing free-breathing in Breast Neoplasms in 140 participants. Completed in 30 January 2020.
30 January 2020
Quick facts
| Lead sponsor | Shu lian Wang |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 140 |
| Start date | 1 January 2017 |
| Primary completion | 30 January 2020 |
| Estimated completion | 30 January 2020 |
| Sites | 2 locations across China |
Drugs / interventions tested
- free-breathing
- deep inspiratory breath-holding
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Heart Injuries — all drugs for Heart Injuries →
- Radiation Toxicity — all drugs for Radiation Toxicity →
Sponsor
Shu lian Wang
Who can join
Adults 18 to 70, female only, with Breast Neoplasms or Heart Injuries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to prospectively investigate the cardiac dose-sparing effect and clinical benefit of deep inspiration breath-hold (DIBH) technique. Patients with left-sided breast cancer treated with breast conserving surgery followed by radiotherapy is enrolled. Radiotherapy is delivered with either free-breathing or deep inspiration breath-hold (DIBH) technique. The cardiac dose parameters and cardiac toxicity are prospective evaluated, and the dose-effect relationship is analyzed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Voluntary Deep Inspiration Breath-Hold (VDIBH) Whole-Breast Irradiation Assisted by Optical Surface Monitoring System (OSMS) in Patients With Left-Sided Breast Cancer: A Prospective Phase II Study.
Zhang JH, Li TT, Qin SR, Liu ZQ, et al · · 2023 · cited 4× · PMID 37312511 · DOI 10.1177/15330338231173773
Verify or expand the search:
- PubMed search for NCT03461588
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Shu lian Wang trials
Trials by the same sponsor.
- NCT05200078 — Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03461588 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shu lian Wang
- Last refreshed: 25 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03461588.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing